Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts

Journal of Lipid Research

Volumn 38, Issue 8, 1997, Pages 1639-1648

  Matzno, Sumio ^a   Yamauchi, Takeshi ^a   Gohda, Maki ^a   Ishida, Naomichi ^a   Katsuura, Kimio ^b   Hanasaki, Yasuaki ^b   Tokunaga, Takumi ^b   Itoh, Hiroyuki ^b   Nakamura, Norifumi ^a  

^a Green Cross Company   (South Korea)

^b TOSOH CORPORATION   (Japan)

Author keywords

HMG CoA reductase inhibitor; Myopathy; Squalene epoxidase inhibitor

Indexed keywords

3 [(3,3' BITHIOPHEN 5 YL)METHOXY] N (6,6 DIMETHYL 2 HEPTEN 4 YNYL) N ETHYLBENZYLAMINE; ENZYME INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; SQUALENE MONOOXYGENASE INHIBITOR; TU 2078; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL VIABILITY; CHOLESTEROL SYNTHESIS; ENZYME INHIBITION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MYOBLAST; MYOPATHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTINS; ANIMALS; APOPTOSIS; BENZYLAMINES; CELL DIFFERENTIATION; CELL LINE; CHOLESTEROL; DNA FRAGMENTATION; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE FIBERS; OXYGENASES; RATS; SIMVASTATIN; SQUALENE MONOOXYGENASE; THIOPHENES;

EID: 0030809606     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rodwell, V. W., J. L. Nordstrom, and J. J. Mitschelen. 1976. Regulation of HMG-CoA reductase. Adv. Lipid Res. 14: 1-74.
2. Wallace, C. S., and B. A. Mueller. 1992. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann. Pharmacother. 26: 190-192.
3. Israeli, A., D. Raveh, R. Arnon, S. Eisenberg, and Y. Stein. 1989. Lovastatin and elevated creatinine kinase: results of rechallenge. Lancet. I: 725.
4. Marias, G. E., and K. K. Larson. 1990. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil combination therapy. Ann. Intern. Med. 112: 228-230.
5. Smith, P. F., R. S. Eydelloth, S. J. Grossmann, R. J. Stubbs, M. S. Schwartz, J. I. Germershausen, K. P. Vyas, P. H. Kari, and J. S. Macdonald. 1991. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporin A interaction and mechanism studies. J. Pharmacol. Exp. Ther. 257: 1225-1235.
6. Munro, E., M. Patel, P. Chan, L. Betteridge, G. Clunn, K. Gallagher, A. Hughes, M. Schachter, J. Wolfe, and P. Sever. 1994. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur. J. Clin. Invest. 24: 766-772.
7. Corsini, A., J. Beitz, A. Granata, R. Fumagalli, H. J. Mest, and R. Paoletti. 1989. Trapidil derivatives and low density lipoprotein metabolism by human skin fibroblasts and by human hepatoma cell line Hep G2. Pharmacol. Res. 21: 521-531.
8. Ryder, N. S. 1991. Squalene epoxidase as a target for the allylamines. Biochem. Soc. Trans. 19: 774-777.
9. Hidaka, Y., T. Satoh, and T. Kamei. 1990. Regulation of squalene epoxidase in HepG2 cells. J. Lipid Res. 31: 2087-2094.
10. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343: 425-430.
11. Horie, M., Y. Sawasaki, H. Fukuzumi, K. Watanabe, Y. Iizuka, Y. Tsuchiya, and T. Kamei. 1991. Hypolipidemic effects of NB-598 in dogs. Atherosclerosis. 88: 183-192.
12. Belo, R. S., J. C. Jamieson, and J. A. Wright. 1993. Studies on the effect of mevinolin (lovastatin) and mevastatin (compactin) on the fusion of L6 myoblasts. Mol. Cell. Biochem. 126: 159-167.
13. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biol. Physiol. 37: 911-917.
14. Biller, S. A., K. Neuenschwander, M. M. Ponpipom, and C. D. Poulter. 1996. Squalene synthase inhibitors. Curr. Pharm. Design. 2: 1-40.
15. Ghirlanda, G., A. Oradei, A. Manto, S. Lippa, L. Uccioli, S. Caputo, A. V. Greco, and G. P. Littarru. 1993. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 33: 226-229.
16. Nakahara, K., M. Kuriyama, H. Yoshidome, K. Nagata, T. Nagado, M. Nakagawa, K. Arimura, I. Higuchi, and M. Osame. 1992. Experimental simvastatin-induced myopathy in rabbits. J. Neurol. Sci. 113: 114-117.
17. Cox, A. D., A. M. Garcia, J. K. Westwick, J. J. Kowalczyk, M. D. Lewis, D. A. Brenner, and C. J. Der. 1994. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem. 269: 19203-19206.
18. Bar-Sagi, D., and J. R. Feramisco. 1985. Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. Cell. 42: 841-848.
19. Noda, M., M. Ko, A. Ogura, D.-G. Liu, T. Amano, T. Takano, and Y. Ikawa. 1985. Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in a neuronal cell line. Nature. 318: 73-75.
20. Pérez-Sala, D., and F. Mollinedo. 1994. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem. Biophys. Res. Commun. 199: 1209-1215.